Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy

NCT02464228 PHASE2 COMPLETED Results posted

Phase II study designed to investigate antitumor activity in terms of objective response rate (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL). Tipifarnib will be administered orally until disease progression.

Details

Lead sponsor	Kura Oncology, Inc.
Phase	PHASE2
Status	COMPLETED
Enrolment	65
Start date	Thu Feb 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Mar 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Relapsed or Refractory Peripheral T-Cell Lymphoma

Interventions

• Tipifarnib

Countries

United States, Spain, South Korea